Please ensure Javascript is enabled for purposes of website accessibility

Why Lannett Stock Is Plunging Today

By Prosper Junior Bakiny - Feb 4, 2021 at 1:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are not impressed with the company's full-year guidance.

What happened

Generic drug manufacturer Lannett (LCI 0.00%) released its financial results for the second quarter of its fiscal year 2021 -- which ended on Dec. 31, 2020 -- after the market closed on Wednesday. And although the company's performance was in line with or above expectations, investors were not pleased with its updated guidance for its full fiscal year 2021. As a result, shares of Lannett are dropping sharply on Thursday and were down by 16.3% as of 1:14 p.m. EST today, after falling by as much as 19.7% earlier in the day.

So what

During the quarter, Lannett recorded net sales of $134 million, compared to the $136 million in sales it recorded during the comparable period of the previous fiscal year. Still, Lannett's top line came in above the $130 million analysts were expecting on average. Meanwhile, the company's adjusted net income was $3.2 million, or $0.08 on a per-share basis. Lannett's adjusted earnings per share (EPS) was right in line with the average analyst estimates. 

Letter blocks spelling "COVID 19" stacked on top of coins.

Image source: Getty Images.

Lannett's updated guideline was the bigger story. For its full fiscal year 2021, the healthcare company now thinks it will record net sales between $480 million and $500 million. Not only is that below its previously announced guidance of net sales between $520 million and $545 million, but it is also well below the $529.32 million in sales analysts were expecting on average.

Now what

Lannett has been dealing with headwinds related to the ongoing pandemic, and its financial results have suffered as a result. After today's plunge, the company's stock is down by 26.6% over the past 12 months. Lannett expects the decline in prescriptions related to the outbreak to "reverse in time," meaning today's sell-off could be a great buying opportunity for investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lannett Company, Inc. Stock Quote
Lannett Company, Inc.
$0.49 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.